Compare ADMA Biologics Inc (ADMA) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs HubSpot Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while HubSpot Inc trades at $198.54 (market cap $10.50B). The key difference: HubSpot Inc is far larger — about 4.9× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | HUBS | |
|---|---|---|
Market Cap | $2.13B | $10.50B |
Sector | Health | Technology |
52-Week High | $20.38 | $560.90 |
52-Week Low | $7.60 | $170.39 |
Enterprise Value | $2.20B | $9.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
HUBS trades at $205.23, up 6.82% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $188 and resistance at $208. Recent earnings beats and 23% revenue growth in Q1 2026 highlight robust execution. Analyst consensus is overwhelmingly bullish with an 80.85% buy rating and a $273.53 price target, suggesting significant upside from current levels.
Outlook remains positive driven by AI integration and customer growth, but high P/E of 102.02 poses valuation risk. Competition from Salesforce and SaaS sector volatility are key concerns. Net income margin improvement to 3.04% in 2025 signals profitability traction, yet investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
